Apellis (APLS) said Wednesday the New England Journal of Medicine published positive Phase 3 results for Empaveli, its treatment for rare kidney diseases.
The study showed a 68% reduction in proteinuria, the presence of an abnormal amount of protein in the urine, at Week 26, along with stabilization of kidney function and reduced C3 staining, the company said.
Results were consistent across adults and adolescents, including patients whose disease returned after a transplant. Empaveli is already Food and Drug Administration-approved for patients 12 and older.
Shares of the company were up over 1% in after-hours trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments